Tuberculosis (TB) in teenagers-an output of old / new national TB program Source: Eur Respir J 2002; 20: Suppl. 38, 216s Year: 2002
A novel nurse-led approach improves treatment completion rates for latent tuberculosis infection (LTBI) treatment Source: International Congress 2014 – Mycobacterium tuberculosis infection: new therapeutic approaches Year: 2014
Estimating costs for treating patients with multi-drug resistant tuberculosis (MDR TB) under the regional tuberculosis control program, Tomsk (Russia) Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015
Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016
The effectiveness of pulmonary TB treatment in patients with organic liver diseases, depending on the way of administration of anti-TB drugs Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe Year: 2016
Could side effects of MDR-TB treatment change the outcome of the disease? Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015
High completion rates with directly observed preventive treatment (DOPT) of latent tuberculosis infection (LTBI) in Ethiopian immigrants (EI) to Israel Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: epidemiology I Year: 2012
Predictive factors of a delayed culture conversion under tuberculosis treatment Source: Annual Congress 2013 –Tuberculosis diagnosis Year: 2013
Home based tuberculosis (TB) care program Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 1 Year: 2014
Is DOTS-Plus effective and cost-effective? Source: Annual Congress 2007 - PG18 - New challenges in fighting tuberculosis in Europe Year: 2007
Tuberculosis treatment outcome monitoring in European Union countries: systematic review Source: Eur Respir J 2013; 41: 635-643 Year: 2013
MDR-TB treatment outcomes in HIV positive patients Source: International Congress 2014 – Tuberculosis: from diagnosis to therapy and prevention Year: 2014
Four cases, one family: A cluster of resistant tuberculosis Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Impact of social support programme on MDR-TB patients' treatment outcomes Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 3 Year: 2014
Prevention of latent TB reactivation in rheumatology patients prior to anti-TNF therapy: Evaluation of a risk stratification strategy in a low prevalence area Source: International Congress 2015 – Screening strategies in TB Year: 2015
Preventing MDRTB in Europe: Drug sensitivities received after the initial phase of treatment Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016
Evaluation of pulmonary TB treatment efficiency depending on polymorphism of glutathione-S-transferasexenobiotic biotransformation enzyme and on sensitivity profile Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics Year: 2016
LATE-BREAKING ABSTRACT: Using virtually observed treatment (VOT) for hard to manage tuberculosis: A pilot study. Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection in subpopulations Year: 2013
Improved treatment outcome of MDR-TB in Eastern Taiwan: Reducing default rate by DOTS Plus Source: Annual Congress 2013 –Tuberculosis: clinical epidemiology and public health Year: 2013
Gene-Xpert for rapid detection of MDR-TB in re-treatment cases;a comparison with standard culture and DST Source: International Congress 2015 – WHO guidelines in TB and clinical practice Year: 2015